Dr. Markus Thiel is currently finishing his residency at university hospital in Homburg, Germany. Simultaneously working on his degree as an oncologist at the clinic of hematology and oncology in Homburg, Germany.
This comprehensive cancer center includes Outpatient Clinic and Day-Care Unit and has an active stem cell transplantation unit.
Dr. Thiel holds degrees in medicine as well as pharmacy from the universities in Bonn and Saarbruecken, both Germany. He started his clinical work at the clinic of oncology at the University Hospital Zurich (USZ) in Zurich, Switzerland. Later he completed his training as a Research Fellow for three years at Queen’s Medical Center in the Laboratory of Cell and Molecular Signaling (LCMS) University of Hawaii, Honolulu, USA.
His main research interest focuses on the modification of T cell activation namely via altering store-operated calcium entry (SOCE) to potentially fine-tune immune response. Dr. Thiel’s background includes antibody technology. He developed bi-specific antibody molecules using phage display technology. His present interest focuses on the Calcium Release Activated Calcium current (I-CRAC) using the patch-clamp technique to study the role of I-CRAC in different malignant diseases.
Dr. Thiel is a member of the German Society for Hematology and Oncology (DGHO) and the American Association of immunologists (AAI).